search
Back to results

INF108F in Infants With Food Protein Induced Proctocolitis (RESTORE)

Primary Purpose

Infant Development, Gut Microbiome, Food Protein Induced Allergic Proctocolitis

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
INF108F probiotic
Placebo
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infant Development

Eligibility Criteria

1 Day - 60 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Infants, male or female, of all ethnic/racial groups, with a gestational period of 37 to 42 weeks Infants aged 1 - 60 days old with a documented FPIAP with either gross blood or microscopic blood in without other possible causes Infants must be exclusively breastfed or at least half of oral intake is from breast feeding or from expressed breast milk A willing parent or legal guardian will sign the consent form either electronically or with a wet ink signature Exclusion Criteria: Infants born earlier than 37 weeks of gestation Infants who are exclusively formula-fed or less than half of oral intake is from breastfeeding or from expressed breast milk at the time of enrollment Infants born with medical complications (i.e., neurological, cerebral palsy, confirmed food allergies) Diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions, gastrointestinal inflammatory conditions, or renal insufficiency History of abdominal surgery or congenital abnormalities of the GI track, the cardiovascular system, the pulmonary system or the renal system Antibiotic use (oral or systemic) within 7 days prior to enrollment Mother's intent to feed non-study probiotics or solid food to their infant at any time during the study Mothers with substance use disorder (SUD) or on Nicotine replacement therapy (NRT) Infants who have consumed any B. infantis-containing probiotics since birth

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    INF108F

    Placebo

    Arm Description

    INF108F

    Placebo

    Outcomes

    Primary Outcome Measures

    Changes to gut microbiome composition
    Changes to the gut microbiome composition in infants with FPIAP over a 4-week period. We will analyze the 16S rRNA of the gut microbiome as well as the short-gun sequencing of metagenomic species of the gut microbiome

    Secondary Outcome Measures

    Changes to clinical symptoms of FPIAP
    Changes to clinical symptoms of FPIAP, specifically we will collect information using questionnaire about infants' GER symptoms, feeding, sleep and stool frequency and consistency. The severity of GER will be quantified using the Infant GER Questionnaire (I-GERQ), with numeric scores, the higher score means more severe GER, the maximum score is 25, scores >7 provide 74% specificity and 94% sensitivity for diagnosing GERD. The sleep will be captured using Infant Sleep Questionnaire, with 0-10 scales, 0 means worst sleep and 10 means excellent sleep for quantify the quality of infant's night sleep.

    Full Information

    First Posted
    March 17, 2023
    Last Updated
    April 5, 2023
    Sponsor
    Massachusetts General Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05793112
    Brief Title
    INF108F in Infants With Food Protein Induced Proctocolitis
    Acronym
    RESTORE
    Official Title
    Restoring Gut Health With INF108F in Infants With Food Protein Induced Allergic Proctocolitis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 1, 2023 (Anticipated)
    Primary Completion Date
    March 1, 2024 (Anticipated)
    Study Completion Date
    March 1, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Massachusetts General Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    Single-center, randomized, double-blind, placebo-controlled trail evaluating INF108F in breastfed infants with FPIAP
    Detailed Description
    This is a single-center, randomized, double-blind, placebo-controlled trial with two arms evaluating IBF108F in breastfed infants with FPIAP. Assessments will be conducted over a 4-week study period with assessment of blood in stool, infant stooling, sleep, feeding, and growth. Safety will be evaluated through collection adverse events.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infant Development, Gut Microbiome, Food Protein Induced Allergic Proctocolitis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    200 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    INF108F
    Arm Type
    Experimental
    Arm Description
    INF108F
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo
    Intervention Type
    Drug
    Intervention Name(s)
    INF108F probiotic
    Intervention Description
    Oral suspension
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Oral suspension
    Primary Outcome Measure Information:
    Title
    Changes to gut microbiome composition
    Description
    Changes to the gut microbiome composition in infants with FPIAP over a 4-week period. We will analyze the 16S rRNA of the gut microbiome as well as the short-gun sequencing of metagenomic species of the gut microbiome
    Time Frame
    Baseline to Day 28
    Secondary Outcome Measure Information:
    Title
    Changes to clinical symptoms of FPIAP
    Description
    Changes to clinical symptoms of FPIAP, specifically we will collect information using questionnaire about infants' GER symptoms, feeding, sleep and stool frequency and consistency. The severity of GER will be quantified using the Infant GER Questionnaire (I-GERQ), with numeric scores, the higher score means more severe GER, the maximum score is 25, scores >7 provide 74% specificity and 94% sensitivity for diagnosing GERD. The sleep will be captured using Infant Sleep Questionnaire, with 0-10 scales, 0 means worst sleep and 10 means excellent sleep for quantify the quality of infant's night sleep.
    Time Frame
    Baseline to day 28

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Day
    Maximum Age & Unit of Time
    60 Days
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Infants, male or female, of all ethnic/racial groups, with a gestational period of 37 to 42 weeks Infants aged 1 - 60 days old with a documented FPIAP with either gross blood or microscopic blood in without other possible causes Infants must be exclusively breastfed or at least half of oral intake is from breast feeding or from expressed breast milk A willing parent or legal guardian will sign the consent form either electronically or with a wet ink signature Exclusion Criteria: Infants born earlier than 37 weeks of gestation Infants who are exclusively formula-fed or less than half of oral intake is from breastfeeding or from expressed breast milk at the time of enrollment Infants born with medical complications (i.e., neurological, cerebral palsy, confirmed food allergies) Diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions, gastrointestinal inflammatory conditions, or renal insufficiency History of abdominal surgery or congenital abnormalities of the GI track, the cardiovascular system, the pulmonary system or the renal system Antibiotic use (oral or systemic) within 7 days prior to enrollment Mother's intent to feed non-study probiotics or solid food to their infant at any time during the study Mothers with substance use disorder (SUD) or on Nicotine replacement therapy (NRT) Infants who have consumed any B. infantis-containing probiotics since birth
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Arsal Khan, BA
    Phone
    617-643-8298
    Email
    akhan51@mgh.harvard.edu

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    31917366
    Citation
    Martin VM, Virkud YV, Seay H, Hickey A, Ndahayo R, Rosow R, Southwick C, Elkort M, Gupta B, Kramer E, Pronchick T, Reuter S, Keet C, Su KW, Shreffler WG, Yuan Q. Prospective Assessment of Pediatrician-Diagnosed Food Protein-Induced Allergic Proctocolitis by Gross or Occult Blood. J Allergy Clin Immunol Pract. 2020 May;8(5):1692-1699.e1. doi: 10.1016/j.jaip.2019.12.029. Epub 2020 Jan 7.
    Results Reference
    result
    PubMed Identifier
    32855350
    Citation
    Martin VM, Virkud YV, Phadke NA, Su KW, Seay H, Atkins MR, Keet C, Shreffler WG, Yuan Q. Increased IgE-Mediated Food Allergy With Food Protein-Induced Allergic Proctocolitis. Pediatrics. 2020 Sep;146(3):e20200202. doi: 10.1542/peds.2020-0202. No abstract available.
    Results Reference
    result
    PubMed Identifier
    25017541
    Citation
    Radano MC, Yuan Q, Katz A, Fleming JT, Kubala S, Shreffler W, Keet CA. Cesarean section and antibiotic use found to be associated with eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2014 Jul-Aug;2(4):475-477.e1. doi: 10.1016/j.jaip.2014.02.018. Epub 2014 May 1. No abstract available.
    Results Reference
    result

    Learn more about this trial

    INF108F in Infants With Food Protein Induced Proctocolitis

    We'll reach out to this number within 24 hrs